It is known that the fundamental mechanism of CDKi-mediated anti-tumor activity is that inhibition of CDK4/6 decreases CDK4/6/cyclin D-induced phosphorylation of pRb, which results in the inhibition of the E2F-mediated transcription of genes involved in G1/S transition [14]. This evidence concerns the gene CDK4 and neoplasm.